Treatments for Homozygous familial hypercholesterolemia
FDA-approved drugs, patient assistance programs, and travel grants tracked on UniteRare for this condition.
ℹ
Treatment data is extracted from FDA drug labels, DailyMed, and openFDA through automated and AI-assisted pipelines that read both structured records and unstructured label text.
Report missing dataFDA-approved treatments (7)
- LeqvioinclisiranNovartis Pharmaceuticals CorporationApproved Feb 2026
- PraluentalirocumabRegeneron Pharmaceuticals, Inc.Approved Oct 2025
- Evkeezaevinacumab-dgnbRegeneron Pharmaceuticals, Inc.Approved Mar 2023
- CrestorrosuvastatiniPR Pharmaceuticals, Inc.Approved May 2016
- RepathaevolocumabAmgen Inc.Approved Aug 2015
- KYNAMROmipomersenKastle Therapeutics, LLCApproved Jan 2013
- JuxtapidlomitapideChiesi Farmaceutici S.p.A.Approved Dec 2012
Patient support programs (6)
Copay cards, manufacturer assistance, and foundation grants. Verification status shown on each card.
KYNAMRO
Kastle Therapeutics, LLC
Unverified — confirm before calling
copay card
copay assistancePatient Assistance
Accepting applications
Praluent
Regeneron Pharmaceuticals, Inc.
Praluent Patient Support (Regeneron Patient Services)
Patient Assistance
Manufacturer Program
Accepting applications
Evkeeza
Regeneron
Familial Hypercholesterolemia
Unverified — confirm before calling
copay card
Copay CardPatient Assistance
Accepting applications
Juxtapid
Chiesi
Familial hypercholesterolemia
Unverified — confirm before calling
copay card
Copay CardPatient Assistance
Accepting applications
Rosuvastatin
AstraZeneca
Familial Hypercholesterolemia
Unverified — confirm before calling
copay card
Copay CardPatient Assistance
Accepting applications
LEQVIO
Novartis
Familial Hypercholesterolemia
Unverified — confirm before calling
copay card
Copay CardPatient Assistance
Accepting applications